Market Newsdesk

VAUGHAN, ON, Dec. 22, 2020 /PRNewswire/ – GFL Environmental Inc. (NYSE: GFL) (TSX: GFL) (“GFL” or the “Company”) today announced the closing of its US$750.0 million principal amount of 3.500% senior secured notes due 2028 (the “Notes”). The net proceeds from the offering of the Notes (the “Notes Offering”) were used repay a portion of amounts outstanding under the Company’s term loan facility due 2025 and to pay related fees and expenses. GFL also announced that it has completed its repricing of the balance of the term loan facility, representing approximately US$1.31 billion, by reducing the LIBOR floor from 1.00% to 0.50%.

The Notes Offering, repayment of a portion of the term loan facility and the term loan repricing will extend the Company’s maturity profile and reduce its annual interest expense by an expected C$13.5 million.

“I am incredibly proud of what our employees have achieved this year”, said Patrick Dovigi, Founder and CEO of GFL. “Even in the face of a global pandemic, we were able to execute on our growth strategy by delivering exceptional financial results, completing accretive acquisitions and reducing our cost of capital with a view to increasing our free cash flow. Raising US$750 million of 3.500% notes due 2028 to repay a portion of our term loan due 2025 and repricing the balance of our term loan are further examples of our commitment to execute on our long-term strategy.” Mr. Dovigi continued, “We have a very supportive group of institutional lenders and debt investors. Since completing our initial public offering earlier this year, we have successfully raised US$1.75 billion, at significantly better rates, to pay for acquisitions and retire more expensive debt.  We also repriced both our revolving credit facility and our term loan facility, making us one of the first North American public companies to reprice a term loan since March 2020.” Mr. Dovigi concluded, “We look forward to starting 2021 with a stronger balance sheet and focused on delivering on our mission to grow the Company, serve our customers safely and create shareholder value over the long-term.”

About GFL

GFL, headquartered in Vaughan, Ontario, is the fourth largest diversified environmental services company in North America, providing a comprehensive line of non-hazardous solid waste management, infrastructure & soil remediation and liquid waste management services through its platform of facilities throughout Canada and in 27 states in the United States. Across its organization, GFL has a workforce of more than 13,000 employees and provides its broad range of environmental services to more than 135,000 commercial and industrial customers and its solid waste collection services to more than 4 million households.

Forward-Looking Statements

This release includes certain “forward-looking statements”, including statements relating to the Company’s growth strategy. In some cases, but not necessarily in all cases, forward-looking statements can be identified by the use of forward looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking statements. Forward-looking statements are not historical facts, nor guarantees or assurances of future performance but instead represent management’s current beliefs, expectations, estimates and projections regarding future events and operating performance. Forward-looking statements are necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by GFL as of the date of this release, are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ, possibly materially, from those indicated by the forward-looking statements include, but are not limited to, the “Risk Factors” section of the Company’s final prospectus relating to its initial public offering dated March 2, 2020 and the Company’s other periodic filings with the SEC and the securities commissions or similar regulatory authorities in Canada. These factors are not intended to represent a complete list of the factors that could affect GFL. However, such risk factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. GFL undertakes no obligation to publicly update any forward-looking statement, except as required by applicable securities laws.

For more information, contact:

View original content to download multimedia:http://www.prnewswire.com/news-releases/gfl-environmental-announces-closing-of-senior-secured-notes-and-repricing-of-term-loan-facility-301197554.html

SOURCE GFL Environmental Inc.

TORONTO, Dec. 22, 2020 /CNW/ – RBC Global Asset Management Inc. (“RBC GAM Inc.”) today announced December 2020 cash distributions for unitholders of RBC ETFs, as follows:

Unitholders of record on December 31, 2020 will receive distributions payable on January 7, 2021.

Please note that the above cash distributions do not include the annual reinvested capital gains distributions for 2020, which are reported separately.

The actual taxable amounts of cash and reinvested distributions for 2020, including the tax characteristics of the distributions, will be reported to brokers (through CDS Clearing and Depository Services Inc.) in early 2021.

For further information regarding RBC ETFs, please visit www.rbcgam.com/etfs.

Commissions, management fees and expenses all may be associated with investments in exchange-traded funds (“ETFs”). Please read the applicable prospectus or ETF Facts document before investing. ETFs are not guaranteed, their values change frequently and past performance may not be repeated. ETF units are bought and sold at market price on a stock exchange and brokerage commissions will reduce returns. RBC ETFs do not seek to return any predetermined amount at maturity. Index returns do not represent RBC ETF returns. RBC ETFs are managed by RBC GAM Inc., a member of the RBC GAM group of companies and an indirect wholly-owned subsidiary of Royal Bank of Canada.

About RBC
Royal Bank of Canada is a global financial institution with a purpose-driven, principles-led approach to delivering leading performance. Our success comes from the 86,000+ employees who leverage their imaginations and insights to bring our vision, values and strategy to life so we can help our clients thrive and communities prosper. As Canada’s biggest bank, and one of the largest in the world based on market capitalization, we have a diversified business model with a focus on innovation and providing exceptional experiences to our 17 million clients in Canada, the U.S. and 34 other countries. Learn more at rbc.com.‎

We are proud to support a broad range of community initiatives through donations, community investments and employee volunteer activities. See how at rbc.com/community-social-impact.

About RBC Global Asset Management

RBC Global Asset Management (RBC GAM) is the asset management division of Royal Bank of Canada (RBC) and includes money managers BlueBay Asset Management and Phillips, Hager & North Investment Management. RBC GAM is a provider of global investment management services and solutions to institutional, high-net-worth and individual investors through separate accounts, pooled funds, mutual funds, hedge funds, exchange-traded funds and specialty investment strategies. The RBC GAM group of companies manage approximately $518 billion in assets and have approximately 1,400 employees located across Canada, the United States, Europe and Asia.

SOURCE RBC Global Asset Management Inc.

NEW YORK, Dec. 22, 2020 /PRNewswire/ — IAC (NASDAQ: IAC) announced today its Board of Directors has approved a plan to spin-off its full stake in Vimeo, the world’s leading video software company, to IAC shareholders. Upon completion, Vimeo will become an independent, separately-traded public company, the 11^th such company to emerge from IAC and its predecessors.  IAC plans to hold a stockholder meeting in the first quarter of 2021 to review and approve a proposal to implement the spin-off, which, if approved, is expected to occur in the second quarter of 2021.

The transaction is anticipated to take the form of a reclassification of IAC shares, with the effect of IAC stockholders receiving a proportionate amount of Vimeo stock. The proposed transaction is intended to qualify as tax-free to IAC and its stockholders for US federal income tax purposes. Further details will be provided in a registration statement on Form S-4 relating to the transaction, which IAC and the new Vimeo holding company will soon file with the Securities and Exchange Commission.

“The combination of Vimeo’s remarkable growth, solid leadership position, and enormous market opportunity have made clear its future,” said Joey Levin, CEO, IAC. “It’s time for Vimeo to spread its wings and become a great independent public company.”

The separation is expected to afford numerous benefits, such as the creation of “pure-play” Vimeo equity currency through which the company could more effectively raise capital as it aims to invest further in product, technology, enterprise sales and international expansion and pursue strategic acquisitions. 

“We have long believed in the power of video to advance human expression and transform businesses,” said Anjali Sud, CEO of Vimeo. “Today we have a rare opportunity to help every team and organization in the world integrate video throughout their operations, across all the ways they communicate and collaborate. Our all-in-one solution radically lowers the barriers of time, cost, and complexity that previously made professional-quality video unattainable. We’re ready for this next chapter and focused on making video far easier and more effective than ever before.”

The proposed transaction is subject to a number of conditions including final approval by IAC’s Board of Directors, approval of the separation proposal by IAC stockholders, and receipt of a tax opinion.  

About Vimeo
Vimeo is the world’s leading all-in-one video software solution. Our platform enables any professional, team, and organization to unlock the power of video to create, collaborate and communicate. We proudly serve our growing community of over 200 million users — from creatives to entrepreneurs to the world’s largest companies. Learn more at www.vimeo.com.

About IAC
IAC (NASDAQ: IAC) builds companies. We are guided by curiosity, a questioning of the status quo, and a desire to invent or acquire new products and brands.  From the single seed that started as IAC over two decades ago have emerged 10 public companies and generations of exceptional leaders.  We will always evolve, but our basic principles of financially-disciplined opportunism will never change.  IAC today operates Vimeo, Dotdash and Care.com, among many others, and has majority ownership of ANGI Homeservices, which includes HomeAdvisor, Angie’s List and Handy.  The Company is headquartered in New York City and has business operations and satellite offices worldwide.

Contact Us

IAC Investor Relations

Mark Schneider

(212) 314-7400

IAC Corporate Communications

Valerie Combs

(212) 314-7361

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

This press release may contain “forward-looking statements” within the meaning of the Federal Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to IAC’s and Vimeo’s anticipated financial performance, objectives, plans and strategies, and all statements (other than statements of historical facts) that address activities, events or developments that IAC and Vimeo intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made by IAC’s and Vimeo’s management in light of their experience and their perception of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate. IAC and Vimeo undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance. Whether actual results will conform to expectations and predictions is subject to known and unknown risks and uncertainties, including: risks and uncertainties discussed in reports that IAC has filed with the SEC; the risks inherent in separating Vimeo from IAC, including uncertainties related to, among other things, the costs and expected benefits of the proposed transaction, the expected timing of the transaction or whether it will be completed, whether the conditions to the transaction can be satisfied or any event, change or other circumstance occurs that could give rise to the abandonment of the proposed spin-off (including the failure to receive any required approvals from the stockholders of IAC), any litigation arising out of or relating to the proposed transaction, the expected tax treatment of the transaction, and the impact of the transaction on the businesses of IAC and Vimeo; and other circumstances beyond IAC’s and Vimeo’s control. You should not place undue reliance on these forward-looking statements. For more details on factors that could affect these expectations, please see IAC’s filings with the SEC, including, once filed, the proxy statement/consent solicitation statement/prospectus.

No Offer or Solicitation / Additional Information and Where To Find It

This communication is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

This communication is being made in respect of a proposed separation of Vimeo, Inc. (“Vimeo”) from the remaining businesses of IAC through the spin-off (the “Spin-off”) of a new Vimeo holding company, Vimeo Holdings, Inc. (“Holdings”), and a merger of Vimeo with a subsidiary of Holdings (the “Merger”). In connection with the Spin-off and the Merger, IAC and Holdings intend to file relevant materials with the Securities and Exchange Commission (the “SEC”), including a joint registration statement on Form S-4 that will include a preliminary proxy statement of IAC and a preliminary consent solicitation statement of Vimeo. The information in the preliminary proxy statement/consent solicitation statement/prospectus will not be complete and may be changed. IAC will deliver the definitive proxy statement and Vimeo will deliver the definitive consent solicitation statement to their respective stockholders as required by applicable law. This communication is not a substitute for any proxy statement, consent solicitation statement or any other document that may be filed with the SEC in connection with the Spin-off or the Merger.

INVESTORS AND SECURITY HOLDERS OF IAC AND VIMEO ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT/CONSENT SOLICITATION STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED SPIN-OFF AND MERGER.

Investors and security holders will be able to obtain these materials (when they are available) and other documents filed with the SEC free of charge at the SEC’s website, www.sec.gov. Copies of documents filed with the SEC by IAC (when they become available) may be obtained free of charge on IAC’s website at www.iac.com.

Participants in the Solicitation

IAC, Vimeo, Holdings and IAC’s directors and executive officers may be deemed to be participants in the solicitation of proxies from IAC’s stockholders in favor of the proposed Spin-off and the solicitation of consents from Vimeo’s stockholders in favor of the proposed Merger under the rules of the SEC. Information about IAC’s directors and executive officers is available in the Registration Statement on Form S-4 which was filed with the SEC by IAC on April 28, 2020.  Additional information regarding participants in the solicitations and a description of their direct and indirect interests will be included in the proxy statement/consent solicitation statement/prospectus and the other relevant documents filed with the SEC when they become available.

View original content to download multimedia:http://www.prnewswire.com/news-releases/iac-announces-plan-to-spin-off-vimeo-to-iac-shareholders-301197537.html

SOURCE IAC

ENGLEWOOD, Colo., Dec. 22, 2020 /PRNewswire/ — WOW! Internet, Cable & Phone (NYSE: WOW), a leading broadband services provider, today announced its popular Android TV-based product, WOW! tv+, is now available to nearly 95 percent of homes across the company’s service footprint.

WOW! tv+ enables customers to enjoy everything a traditional TV experience offers plus cloud DVR functionality, voice control, music and access to hundreds of apps, and games. Now customers can access all their favorite entertainment with an enhanced viewing experience and curated content. Customers can also enjoy WOW! tv+ at an affordable price, making it easier for WOW! customers to choose an offering that fits their budget.

WOW! tv+ customers have access to a voice remote with Google Assistant, Netflix integration and dozens of streaming services and apps through the Google Play Store with no change of input needed. WOW! tv+ also recently launched on Amazon’s Fire TV stick, which allows users to download the “Watch WOW!” app to start watching their favorite WOW! tv+ subscribed content.

Since its initial launch in Columbus, Ohio in March of this year, WOW! tv+ has proven to be a top choice for thousands of WOW! customers looking to enhance their service capabilities. Customers have access to complete live channel packages, tailored to their preferences with a cloud DVR, and a vast selection of additional content through WOW! tv+’s On Demand library. The intuitive content discovery interface enables customers to easily navigate and choose the entertainment they want.

WOW! tv+ is currently available in the following markets:

• Auburn, Huntsville and Montgomery, Alabama
• Augusta, Columbus and Fort Gordon, Georgia
• Charleston, South Carolina
• Chicago, Illinois
• Columbus and Cleveland, Ohio
• Evansville, Indiana
• Knoxville, Tennessee
• Mid-Michigan and Southeast Michigan
• Pinellas and Panama City, Florida

“We’re thrilled that our customers in these markets are enjoying our WOW! tv+ offering as their chosen alternative to the traditional cable TV experience,” said Teresa Elder, CEO of WOW!. “With families staying home now more than ever, customers can choose how and when they consume their entertainment with the satisfaction of knowing they are backed by our reliable high-speed data network. We’re looking forward to expanding WOW! tv+ to additional markets and even more customers in the future.”

Learn more about WOW! tv+: https://www.wowway.com/support/tv/wowtv.

About WOW! Internet, Cable & Phone
WOW! is one of the nation’s leading broadband service providers, with an efficient, high-performing network that passes three million residential, business and wholesale consumers. WOW! provides services in 19 markets, primarily in the Midwest and Southeast, including Illinois, Michigan, Indiana, Ohio, Maryland, Alabama, Tennessee, South Carolina, Florida and Georgia. With an expansive portfolio of advanced services, including high-speed Internet services, cable TV, streaming, phone, business data, voice, and cloud services, the company is dedicated to providing outstanding service at affordable prices. WOW! also serves as a leader in exceptional human resources practices, having been recognized by the National Association for Business Resources’ for six years as a Best & Brightest Company to Work For, winning the award for the last two consecutive years. Visit wowway.com for more information.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/wow-tv-video-service-now-available-in-nearly-95-of-wows-footprint-301197389.html

SOURCE WideOpenWest, Inc.

THOUSAND OAKS, Calif., Dec. 22, 2020 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for sotorasib, an investigational KRAS^G12C inhibitor, for the treatment of adult patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).

“Just over two years since the first patient was dosed, sotorasib is now on track to potentially be the first approved targeted therapy for patients with previously treated NSCLC harboring the KRAS G12C mutation,” said David M. Reese, M.D., executive vice president of Research and Development at Amgen. “With this submission to EMA, Amgen is continuing to rapidly advance the KRAS^G12C inhibitor clinical program to bring this innovative potential therapy to patients globally as quickly as possible.”

KRAS G12C is the most common KRAS mutation in NSCLC.¹ Approximately 13% of patients with NSCLC harbor the KRAS G12C mutation and each year approximately 33,000 new patients in the EU-27 are diagnosed with KRAS G12C-mutated NSCLC.^1,2 There is a high unmet need and poor outcomes in the second-line treatment of KRAS G12C-driven NSCLC and, currently, there are no KRAS G12C targeted therapies approved.^3,4,5

The submission is supported by positive Phase 2 results in patients with locally advanced or metastatic NSCLC with KRAS G12C mutation from the CodeBreaK 100 clinical study, whose cancer had progressed despite prior treatment with chemotherapy and/or immunotherapy. In the Phase 1 study, treatment with sotorasib provided durable anticancer activity with a positive benefit-risk profile.⁶ These results will be presented at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer (WCLC) Presidential Symposium in January 2021.

About Sotorasib
Amgen has taken on one of the toughest challenges of the last 40 years in cancer research by developing sotorasib, an investigational KRAS^G12C inhibitor.⁷ Sotorasib was the first KRAS^G12C inhibitor to enter the clinic and is being studied in the broadest clinical program exploring 10 combinations with global sites spanning four continents. In just over two years, the sotorasib clinical program CodeBreaK has established the deepest clinical data set with more than 600 patients studied across 13 tumor types.

Sotorasib has demonstrated a positive benefit-risk profile with fast, deep and durable anticancer activity in patients with advanced non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation with a once daily oral formulation. Promising responses have also been observed in multiple other solid tumors.⁷

About CodeBreaK
The CodeBreaK clinical development program for Amgen’s investigational drug sotorasib is designed to treat patients with an advanced solid tumor with the KRAS G12C mutation and address the longstanding unmet medical need for these cancers. As the most advanced KRAS G12C clinical development program, CodeBreaK has enrolled more than 600 patients across 13 tumor types since its inception.

CodeBreaK 100, the Phase 1 and 2, first-in-human, open-label multicenter study, enrolled patients with KRAS G12C-mutated solid tumors. Eligible patients must have received a prior line of systemic anticancer therapy, consistent with their tumor type and stage of disease. The primary endpoint for the Phase 2 study was centrally assessed objective response rate. The Phase 2 trial in NSCLC enrolled 126 patients, 123 of whom had centrally evaluable lesions by RECIST at baseline. The Phase 2 trial in colorectal cancer (CRC) is fully enrolled and topline results are expected in 2021.

A global Phase 3 randomized active-controlled study comparing sotorasib to docetaxel in patients with KRAS G12C-mutated NSCLC (CodeBreaK 200) is currently recruiting. Amgen also has several Phase 1b combination studies across various advanced solid tumors (CodeBreaK 101) open for enrollment.

For information, please visit www.codebreaktrials.com.

About Amgen Oncology
Amgen Oncology is searching for and finding answers to incredibly complex questions that will advance care and improve lives for cancer patients and their families. Our research drives us to understand the disease in the context of the patient’s life – not just their cancer journey – so they can take control of their lives.

For the last four decades, we have been dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer. Building on our heritage, Amgen continues to advance the largest pipeline in the Company’s history, moving with great speed to advance those innovations for the patients who need them.

At Amgen, we are driven by our commitment to transform the lives of cancer patients and keep them at the center of everything we do.

To learn more about Amgen’s innovative pipeline with diverse modalities and genetically validated targets, please visit AmgenOncology.com. For more information, follow us on www.twitter.com/amgenoncology.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company, including BeiGene, Ltd. or any collaboration or potential collaboration in pursuit of therapeutic antibodies against COVID-19 (including statements regarding such collaboration’s, or our own, ability to discover and develop fully-human neutralizing antibodies targeting SARS-CoV-2 or antibodies against targets other than the SARS-CoV-2 receptor binding domain, and/or to produce any such antibodies to potentially prevent or treat COVID-19), or the Otezla® (apremilast) acquisition (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, outcomes, progress, or effects relating to studies of Otezla as a potential treatment for COVID-19, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.

Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Further, any scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses.

CONTACT: Amgen, Thousand Oaks
Trish Rowland, 805-447-5631 (Media)
Jessica Akopyan, 805-447-0974 (Media)
Arvind Sood, 805-447-1060 (Investors)

References

¹ European Cancer Information System. Data explorer. Incidence and mortality 2020. EU-27. Available at: https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-AE27$2-All$4-1,2$3-All$6-0,85$5-2008,2008$7-7,8$CEstByCancer$X0_8-3$CEstRelativeCanc$X1_8-3$X1_9-AE27 Accessed December 2020.
² Lung Cancer Europe. Types of lung cancer and staging. Available at: https://www.lungcancereurope.eu/lung-cancer/types-of-lung-cancer-and-staging/ Accessed December 2020.
³ Aggarwal S, et al. Presented at: The European Society for Medical Oncology; September 2020; Virtual Congress. Poster 1339P.
⁴ McCormick F. K-Ras protein as a drug target. J Mol Med (Berl). 2016;94(3):253-258.
⁵ Román M, Baraibar I, López I, et al.  KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Mol Cancer. 2018;17(1):33. 
⁶ Hong DS, et al. N Engl J Med. 2020; 383:1207-1217.
⁷ Kim D, et al. Cell. 2020;183 :850-859.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/amgen-submits-sotorasib-marketing-authorization-application-to-the-european-medicines-agency-301196985.html

SOURCE Amgen

AIRPORT CITY, Israel, Dec. 22, 2020 /PRNewswire/ — My Size, Inc, (the “Company” or “My Size”) (NASDAQ: MYSZ) (TASE: MYSZ) the developer and creator of AI-driven sizing measurement solutions, today announced the planned launch of its e-commerce shoe sizing solution, based on the company’s highly accurate, AI-driven sizing solution. The footwear measurement solution can be easily integrated with all leading e-commerce platforms and is expected to be available in Q1 2021.

 

 

Online shoe sales in the U.S. market are estimated to be $20.9 billion this year growing nearly 10% since 2019. Yet despite online footwear’s promising sales, customer-friendly policies like “free two-way-shipping”, put stress on profit margins and place a cloudy ceiling over future prospects, if the issue remains unaddressed.

The MySize footwear sizing solution is easy to implement and is “plug and play” with leading e-commerce platforms Shopify, WooCommerce, Lightspeed, Magento and more. By pairing a footwear retail’s product table, GTIN, description, and other relevant details with MySize’s AI-driven and machine learning algorithms online shoppers will be presented with a highly accurate size recommendation, which is expected to increase confidence, and, reduce returns.

MySize has repeatedly demonstrated the positive impact of its highly accurate online sizing solution in the online apparel industry, reducing returns by as much as 50%, and increasing average order value by as much as 30%. Utilizing this same technology, MySize’s footwear solution enables customers to receive a highly accurate shoe size recommendation that is saved, after providing as few details as their size in a favorite shoe or even a picture of their foot.

“As e-commerce booms, so do returns, and footwear returns are often outsized within the already high return rates for the online apparel industry, costing apparel and footwear retailers dearly and adding to customer frustration.” said Ronen Luzon, CEO and Founder of MySize. “With the planned launch of our shoe sizing solution, footwear retailers will finally be able to seamlessly and proactively address the problem and cut return costs, while providing a more confident shopping experience in the process.”

For the latest news coverage, please follow the Company on Facebook, LinkedIn, Instagram and Twitter.

About MySize Inc:

My Size, Inc. (TASE: MYSZ) (NASDAQ: MYSZ) has developed a unique measurement technology based on sophisticated algorithms and cutting-edge technology with broad applications, including the apparel, e-commerce, DIY, shipping, and parcel delivery industries. This proprietary measurement technology is driven by several algorithms that are able to calculate and record measurements in a variety of novel ways. To learn more about My Size, please visit our website: www.mysizeid.com. We routinely post information that may be important to investors in the Investor Relations section of our website. Follow us on Facebook, LinkedIn, Instagram and Twitter

Please click here for a demonstration of how MySizeID provides a full sizing solution for the retail industry.

Register here for a one-month free trial of MySizeID solution for your online store.

Please click here to download MySizeID for iOS.

Please click hereto download MySizeID for Android.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements. All forward-looking statements speak only as of the date of this press release. You should not place undue reliance on these forward-looking statements. Although we believe that our plans, objectives, expectations and intentions reflected in or suggested by the forward-looking statements are reasonable, we can give no assurance that these plans, objectives, expectations or intentions will be achieved. Forward-looking statements involve significant risks and uncertainties (some of which are beyond our control) and assumptions that could cause actual results to differ materially from historical experience and present expectations or projections. Actual results to differ materially from those in the forward-looking statements and the trading price for our common stock may fluctuate significantly. Forward-looking statements also are affected by the risk factors described in the Company’s filings with the U.S. Securities and Exchange Commission. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

U.S. Press Contact:
Strauss Communications
[email protected] 
www.strausscomms.com

My Size Investor relations contact:
Or Kles, CFO
[email protected] 

View original content:http://www.prnewswire.com/news-releases/mysize-to-add-highly-accurate-online-footwear-sizing-to-ecommerce-solution-301197423.html

SOURCE My Size Inc.

SEATTLE, Dec. 22, 2020 /PRNewswire/ — Boeing [NYSE: BA] and Alaska Airlines announced that the carrier is buying 23 more 737-9 airplanes, building on its original order and an agreement last month to acquire new 737-9s through lease. The new deal brings Alaska Airlines’ total 737 MAX orders and options to 120 airplanes, which will give the fifth largest U.S. carrier the scale, efficiency and flexibility to expand as air travel recovers.

“We are extremely proud to be announcing this transformative agreement with Boeing,” said Brad Tilden, CEO of Alaska Air Group. “We believe in this airplane, we believe in our strong partnership with Boeing, and we believe in the future of Alaska Airlines and the incredible opportunities ahead as we climb our way out of this pandemic.”

Alaska Airlines, a longtime Boeing 737 operator, placed an order for 32 737-9 jets in 2012 as part of its fleet modernization program. The 737-9 is a member of the 737 MAX family that is designed to offer more fuel efficiency, reliability and flexibility in the single-aisle airplane market. Last month, Alaska Airlines announced it is expanding its commitment to the 737 MAX program by leasing 13 new 737-9s while selling some A320 jets it had taken on through its acquisition of Virgin America.

The new agreement announced today will add 23 firm orders for the 737-9 and more options for future purchases. In all, Alaska will have 52 options which, if fully exercised, would take the carrier to as many as 120 737 MAX airplanes. The airline said the deal moves it toward a more efficient, all-Boeing mainline fleet that will “enhance the guest experience, improve operational performance and support the company’s growth.”

“We could not ask for a better partner than Boeing and we are delighted to be standing side by side with them as we work together to get our economy back on its feet,” said Tilden.

Alaska Airlines and Boeing leaders announced the agreement during a signing ceremony at Boeing’s delivery facility in Seattle, flanked by a new 737-9 that will be among the first such jets to be operated by Alaska Airlines. In observance of COVID-19 restrictions, both companies limited attendance at the event and addressed the pandemic that has severely affected air travel, expressing confidence in the fundamental strength of the industry and long-term passenger demand.

“Alaska Airlines has done a tremendous job of weathering the impacts from the COVID-19 pandemic, and is well positioned to return to its growth trajectory and strengthen its standing as one of the top U.S. airlines. With Alaska’s industry-leading reputation for safety, sustainability and customer service, we are honored they have chosen to invest in their future with a significant purchase of additional Boeing 737 airplanes,” said Stan Deal, president and CEO of Boeing Commercial Airplanes. “We are grateful for Alaska’s trust and partnership. Our team is focused on delivering their first 737 MAX jets and helping ensure a safe and seamless entry into service.”

Alaska Airlines says the 737 – equipped with new, more fuel-efficient engines and improved aerodynamics – will use 20% less fuel and reduce emissions by 20% per seat compared to airplanes it replaces. The airline will configure the jet with 178 seats in a three-class configuration. The plane can fly 3,550 nautical miles, about 600 miles more than its predecessor. This additional capability will allow airlines to offer new and more direct routes to passengers. Every airplane will feature the new Boeing Sky Interior, highlighted by modern sculpted sidewalls and window reveals, LED lighting that enhances the sense of spaciousness and larger pivoting overhead storage bins.

Learn more about Alaska’s confidence in the safety and certification of the MAX at alaskaair.com/737MAX. 

Total orders: 68 737 MAX Aircraft

Total options: 52 737 MAX Aircraft

About Boeing
Boeing is the world’s largest aerospace company and leading provider of commercial airplanes, defense, space and security systems, and global services. As a top U.S. exporter, the company supports commercial and government customers in more than 150 countries, leveraging the talents of a global supplier base. Building on a legacy of aerospace leadership, Boeing continues to lead in technology and innovation, deliver for its customers and invest in its people and future growth.

About Alaska Airlines
Alaska Airlines and its regional partners serve more than 115 destinations across the United States and North America. The airline provides essential air service for our guests along with moving crucial cargo shipments, while emphasizing Next-Level Care. Alaska is known for low fares, award-winning customer service and sustainability efforts. Guests can earn and redeem miles on flights to more than 800 destinations worldwide with Alaska and its Global Partners. On March 31, 2021, Alaska will officially become a member of the oneworld global alliance. Learn more about Alaska at newsroom.alaskaair.com and blog.alaskaair.com. Alaska Airlines and Horizon Air are subsidiaries of Alaska Air Group (NYSE: ALK).

Contact:
Jessica Kowal
Boeing Communications
(206) 660-6849
[email protected]

Joe Loeffler

Boeing Communications
(425) 306-2145
[email protected]

 

View original content:http://www.prnewswire.com/news-releases/alaska-airlines-boosts-737-max-orders-and-options-to-120-jets-301197524.html

SOURCE Boeing

SAN JOSE, Calif., Dec. 22, 2020 /PRNewswire/ — Today eBay delivers a Christmas sneaker surprise – a virtual holiday drop, launching in partnership with NBA champion and sneakerhead Anthony Davis. eBay’s “Santa Sneaker Drop” kicks off with a digital short featuring Santa himself asking Davis for an assist delivering this season’s hottest collectible kicks. As the story goes, Davis ran into some trouble handling the sleigh, and when he swerved mid-flight, more than 500 pairs of the most coveted sneakers fell off the sleigh and scattered across the country. Santa was not happy. 

To make things right, Davis is partnering with eBay to turn the dropped sneakers into a holiday sneaker drop – all in AR (augmented reality) for sneakerheads to post up and play. Now through December 24th, this virtual event will allow people to score one of 500 pairs of must-have kicks – including the Air Jordan 1 Travis Scott, the Nike Air Max 97 Sean Wotherspoon, and even the Jordan 1 Off-White Chicago. 

“I never imagined having a chance to team up with the greatest big man of all time, and I’m grateful that eBay has given me this once in a lifetime opportunity to work with Santa this holiday,” said NBA star Anthony Davis. “Sneakers are at the top of millions of wish lists this year, and we’re hoping to make holiday dreams come true for sneakerheads across the country.”

How to Score
Using augmented reality, people can participate in the drop from absolutely anywhere. Activate the experience with your camera and open a virtual sneaker box that comes down the chimney to see if you’ve snagged a pair. Everyone gets five chances per day for three days, so if you don’t score right away, keep trying to win. Visit the Santa Sneaker Drop site from an iOS or Android mobile device starting at 12pm ET on December 22nd and follow the step-by-step instructions. The virtual event ends at 11:59pm ET on December 24^th. 

Spreading Cheer
eBay also teamed up with Soles4Souls to get 40,000 pairs of new athletic sneakers to kids experiencing homelessness in the US. Soles4Souls distributes new shoes to those in need across the country, and research shows that sneakers positively impact how children see themselves. Nearly all the kids in this program said they feel happier and more confident after receiving their new shoes – and they are more likely to play sports.  

“For most kids, having the right sneakers to wear for a game of pickup basketball is a given,” said Buddy Teaster, President and CEO, Soles4Souls. “But that’s not the case when families are struggling with homelessness. We believe every kid deserves to have their basic needs met – including a pair of shoes on their feet. This donation couldn’t come at a better time, and a superstar like Anthony Davis brings a whole new level of awareness to our program.”

Many of the shoes donated by eBay will be given to kids in Davis’ hometown of Chicago and his current town, Los Angeles.

The Real Deal
The Santa Sneaker Drop is happening on the heels of eBay’s expansion of Authenticity Guarantee for sneakers. With this service, all new and pre-owned collectible sneakers sold on eBay for over $100 in the U.S. will be fully vetted and verified by an independent team of industry experts.

Check out eBay.com/SantaSneakerDrop for Official Rules and more information. Must be 18+. For news and to shop eBay’s incredible selection of sneakers, check out eBay.com/sneakers and follow @eBay on Instagram, Twitter, YouTube, TikTok and Facebook.

eBay Sneakers By the Numbers

• On average, there are more than half a million sneaker listings on eBay each day.
• eBay sells a sneaker every 1.5 seconds.
• Sneakers are surging in popularity around the world and are a top enthusiast category on the marketplace.
• In 2019, eBay sold nearly six million sneakers in North America.
• eBay sells millions of sneakers a year, making the marketplace one of the largest channels to buy and sell sneakers.

About eBay
eBay Inc (NASDAQ: EBAY) is a global commerce leader including the Marketplace and Classifieds platforms. Collectively, we connect millions of buyers and sellers around the world, empowering people and creating opportunity for all. Founded in 1995 in San Jose, California, eBay is one of the world’s largest and most vibrant marketplaces for discovering great value and unique selection. For more information about the company and its global portfolio of online brands, visit www.ebayinc.com.

Soles4Souls
Soles4Souls turns unwanted shoes and clothing into opportunity by keeping them from going to waste and putting them to good use: providing relief, creating jobs and empowering people to break the cycle of poverty. Headquartered in Nashville, Tennessee, the organization repurposes product to supply its micro-enterprise, disaster relief, and direct assistance programs. With locations and warehouses across three continents, Soles4Souls has been able to distribute more than 51 million pairs of shoes and pieces of clothing in 129 countries since 2006. Visit soles4souls.org for more information.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/ebay-and-anthony-davis-surprise-sneakerheads-with-last-minute-christmas-drop-301197532.html

SOURCE eBay Inc.